These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 22166325)

  • 1. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
    Koc G; Wang X; Luo Y
    Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma.
    LaPlant KD; Louzon PD
    Ann Pharmacother; 2010 Jun; 44(6):1054-60. PubMed ID: 20407031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.
    Sonpavde G; Hutson TE; Sternberg CN
    Expert Opin Investig Drugs; 2008 Feb; 17(2):253-61. PubMed ID: 18230058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma.
    Bukowski RM
    Expert Rev Anticancer Ther; 2010 May; 10(5):635-45. PubMed ID: 20469994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pazopanib in renal cell carcinoma.
    Ward JE; Stadler WM
    Clin Cancer Res; 2010 Dec; 16(24):5923-7. PubMed ID: 21059813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
    Keisner SV; Shah SR
    Drugs; 2011 Mar; 71(4):443-54. PubMed ID: 21395357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma.
    Bourdeanu L; Twardowski P; Pal SK
    Clin J Oncol Nurs; 2011 Oct; 15(5):513-7. PubMed ID: 21951737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.
    Jedeszko C; Paez-Ribes M; Di Desidero T; Man S; Lee CR; Xu P; Bjarnason GA; Bocci G; Kerbel RS
    Sci Transl Med; 2015 Apr; 7(282):282ra50. PubMed ID: 25855496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib for the treatment of advanced renal cell carcinoma.
    Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
    Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pazopanib: a new multiple tyrosine kinase inhibitor in the therapy of metastatic renal cell carcinoma and other solid tumors.
    Melichar B; Studentová H; Zezulová M
    J BUON; 2011; 16(2):203-9. PubMed ID: 21766486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
    Zivi A; Cerbone L; Recine F; Sternberg CN
    Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pazopanib: in advanced renal cell carcinoma.
    Sanford M; Keating GM
    BioDrugs; 2010 Oct; 24(5):279-86. PubMed ID: 20649181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pazopanib: therapeutic developments.
    Limvorasak S; Posadas EM
    Expert Opin Pharmacother; 2009 Dec; 10(18):3091-102. PubMed ID: 19954277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.
    Bukowski RM
    Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib. Kidney cancer: many risks, but is there a benefit for patients?
    Prescrire Int; 2011 Mar; 20(114):64-6. PubMed ID: 21648224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib for the treatment of renal cancer.
    Strumberg D
    Expert Opin Pharmacother; 2012 Feb; 13(3):407-19. PubMed ID: 22263843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell cancer (SWITCH-2 - AN 33/11)].
    Rexer H
    Urologe A; 2012 May; 51(5):724-6. PubMed ID: 22576149
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.